<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3034">
  <stage>Registered</stage>
  <submitdate>23/12/2010</submitdate>
  <approvaldate>23/12/2010</approvaldate>
  <nctid>NCT01266525</nctid>
  <trial_identification>
    <studytitle>Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil</studytitle>
    <scientifictitle>A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2010-022596-64</secondaryid>
    <secondaryid>DRI10734</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Dementia Alzheimer's Type</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - SAR110894
Treatment: drugs - placebo (for SAR110894)
Treatment: drugs - Donepezil

Experimental: SAR110894 - 0.5 mg - SAR110894, 0.5 mg once daily along with Donepezil.

Experimental: SAR110894 - 2 mg - SAR110894, 2 mg once daily along with Donepezil.

Experimental: SAR110894 - 5 mg - SAR110894, 5 mg once daily along with Donepezil.

Placebo Comparator: Placebo - Placebo (for SAR110894) once daily along with Donepezil.


Treatment: drugs: SAR110894
Pharmaceutical form: Capsule
Route of administration: Oral

Treatment: drugs: placebo (for SAR110894)
Pharmaceutical form: Capsule
Route of administration: Oral

Treatment: drugs: Donepezil
5 mg or 10 mg once daily continued as taken before inclusion

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline to Week 24 in the standard 11-item total score from the 13-item Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog).</outcome>
      <timepoint>Week 4, 12, and 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) global score</outcome>
      <timepoint>Week 4, 12, and 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in each of the two remaining items of the ADAS-Cog (namely "delayed word recall" and "concentration/distractibility")</outcome>
      <timepoint>Week 4, 12, and 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in each of the five factors from the Cognitive Drug Research System (CDR-S) computerized assessment</outcome>
      <timepoint>Week 4, 12, and 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the Mini Mental State Examination (MMSE) total score</outcome>
      <timepoint>Week 4, 12, and 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Patients with diagnosis of Alzheimer's Disease (AD) (Cannot be dementia from strokes
             or other causes).

          -  Patient is on stable and well-tolerated donepezil treatment at a dose of either 5 or
             10 mg daily for at least 3 months prior to screening visit.</inclusivecriteria>
    <inclusiveminage>55</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Age &lt;55 years old.

          -  Psychotic features, agitation, or behavioral problems within the last 3 months.

          -  Patients unable to comply with ophthalmologic monitoring.

          -  Lack of consistent and reliable caregiver.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>291</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Investigational Site Number 036002 - Adelaide</hospital>
    <hospital>Investigational Site Number 036007 - Chermside</hospital>
    <hospital>Investigational Site Number 036008 - Heidelberg West</hospital>
    <hospital>Investigational Site Number 036006 - Herston</hospital>
    <hospital>Investigational Site Number 036001 - Nedlands</hospital>
    <hospital>Investigational Site Number 036004 - Randwick</hospital>
    <hospital>Investigational Site Number 036009 - Toowoomba</hospital>
    <hospital>Investigational Site Number 036005 - Waratah</hospital>
    <hospital>Investigational Site Number 036003 - Woodville</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>4032 - Chermside</postcode>
    <postcode>3081 - Heidelberg West</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>4350 - Toowoomba</postcode>
    <postcode>2298 - Waratah</postcode>
    <postcode>5011 - Woodville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Vermont</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Calgary</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Gatineau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Greenfield Park</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Halifax</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ottawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Regina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Sherbrooke</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>St. John</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Limoges</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse Cedex 3</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Schwerin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Würzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ancona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Castellanza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Cefalù</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdynia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Szczecin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Amadora</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Algorta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Terrassa</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Primary Objective:

      - To demonstrate the efficacy of at least one dose of SAR110894 (H3 receptor antagonist) in
      comparison to placebo on cognitive performance in patients with mild to moderate Alzheimer's
      disease (AD) while on stable donepezil therapy

      Secondary Objectives:

        -  To explore the effect of SAR110894 on functional impairment, global clinical status and
           behavioral disturbances;

        -  To assess the safety/tolerability of SAR110894;

        -  To assess pharmacokinetic (PK) of SAR110894 and concentrations of donepezil;

        -  To explore caregiver time consumption and distress changes.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01266525</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Sciences &amp; Operations</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>